Acción ASLN ASLAN PHARMACEUTICALS LIMITED
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas ASLAN Pharmaceuticals Limited

Acciones

ASLN

US04522R2004

Mercado cerrado - Nasdaq
Otros sitios de cotización
 22:00:00 29/04/2024 		Varia. Cinco días. Varia. 1 de enero.
0,457 USD +10,04 % Gráfico intradía de ASLAN Pharmaceuticals Limited +0,44 % -12,47 %
29/04 La renta variable asiática cotizó en EE.UU. como los recibos de depósito estadounidenses abren la semana con un tono plano en la negociación del lunes MT
26/04 La renta variable asiática negociada en EE.UU. como recibos de depósito estadounidenses tiende al alza en la jornada del viernes y termina la semana con una subida del 3,5 MT

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab
Asian Equities Traded in the US as American Depositary Receipts Open Week on Flat Note in Monday Trading
Asian Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.5%
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Lower in Thursday Trading
ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference
Technology Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading
Asian Equities Traded in the US as American Depositary Receipts Open Week Higher
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice - April 19, 2024
ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
ASLAN Pharmaceuticals Announces Positive Interim Results from Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
ASLAN PHARMACEUTICALS : ANNOUNCES POSITIVE INTERIM RESULTS FROM PHASE 2 STUDY OF EBLASAKIMAB IN DUPILUMAB-EXPERIENCED ATOPIC DERMATITIS PATIENTS - Form 6-K
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice
ASLAN PHARMACEUTICALS : ANNOUNCES RECEIPT OF NASDAQ NOTICE - Form 6-K
Asian Equities Traded in the US as American Depositary Receipts Fall Again in Friday Trading
Asian Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading
Asian Equities Traded in the US as American Depositary Receipts Remain Flat in Wednesday Trading
Financial, Telecoms Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Sharply Lower Tuesday
Asian Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and provides corporate update
Asian Equities Traded in the US as American Depositary Receipts Fall in Friday Trading
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción ASLN
  4. Noticias ASLAN Pharmaceuticals Limited
  5. Otros idiomas